Positive News Sentiment NASDAQ:ERYP ERYTECH Pharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. $1.12 0.00 (0.00%) (As of 07/1/2022 03:59 PM ET) Add Compare Share Today's Range$1.09▼$1.1250-Day Range$1.03▼$1.6852-Week Range$0.98▼$9.50Volume6 shsAverage Volume488,761 shsMarket Capitalization$34.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ERYTECH Pharma MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.24% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.08) to ($1.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.67 out of 5 starsMedical Sector1197th out of 1,427 stocksBiological Products, Except Diagnostic Industry188th out of 218 stocks 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for ERYTECH Pharma. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.24% of the outstanding shares of ERYTECH Pharma have been sold short.Short Interest Ratio / Days to CoverERYTECH Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ERYTECH Pharma has recently decreased by 9.48%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldERYTECH Pharma does not currently pay a dividend.Dividend GrowthERYTECH Pharma does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ERYP. Previous Next 2.7 News and Social Media Coverage News SentimentERYTECH Pharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ERYTECH Pharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ERYP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ERYTECH Pharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 30.13% of the stock of ERYTECH Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ERYTECH Pharma are expected to grow in the coming year, from ($2.08) to ($1.97) per share.Price to Book Value per Share RatioERYTECH Pharma has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ERYP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address About ERYTECH Pharma (NASDAQ:ERYP) StockERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.Read More ERYP Stock News HeadlinesJune 24, 2022 | finance.yahoo.comReport – ERYTECH’s Combined Shareholders’ Meeting On June 24, 2022June 3, 2022 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _May 31, 2022.May 24, 2022 | finance.yahoo.comERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022May 17, 2022 | finanznachrichten.deErytech Pharma S.A.: ERYTECH to Present at the H.C. Wainwright Global Investment ConferenceMay 17, 2022 | finance.yahoo.comERYTECH to Present at the H.C. Wainwright Global Investment ConferenceMay 13, 2022 | seekingalpha.comERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2022 Results - Earnings Call TranscriptMay 13, 2022 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital – April 30, 2022May 12, 2022 | nz.finance.yahoo.comERYTECH Provides Business and Financial Update for the First Quarter of 2022May 12, 2022 | finanznachrichten.deErytech Pharma S.A.: ERYTECH Provides Business and Financial Update for the First Quarter of 2022May 12, 2022 | seekingalpha.comErytech Pharma reports Q1 resultsMay 12, 2022 | finance.yahoo.comERYTECH Provides Business and Financial Update for the First Quarter of 2022April 28, 2022 | finance.yahoo.comERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendarApril 27, 2022 | seekingalpha.comNkarta, ERYTECH Pharma top healthcare gainers; Eliem, Clarus lead losers' packApril 25, 2022 | investorplace.comWhy Is ERYTECH Pharma (ERYP) Stock Up Today?April 25, 2022 | finanznachrichten.deErytech Pharma S.A.: ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with CatalentApril 6, 2022 | finance.yahoo.comERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of HaematologyApril 6, 2022 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital – March 31, 2022April 6, 2022 | finance.yahoo.comERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of HaematologyApril 4, 2022 | apnews.comERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell SocietyApril 4, 2022 | finance.yahoo.comERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell SocietyMarch 28, 2022 | finanznachrichten.deErytech Pharma S.A.: ERYTECH to Participate in the Upcoming April Investor ConferencesMarch 28, 2022 | finance.yahoo.comERYTECH to Participate in the Upcoming April Investor ConferencesMarch 14, 2022 | seekingalpha.comERYTECH Pharma S.A. 2021 Q4 - Results - Earnings Call PresentationMarch 14, 2022 | seekingalpha.comErytech Pharma reports Q4 resultsMarch 13, 2022 | finanznachrichten.deErytech Pharma S.A.: ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ERYP CUSIPN/A CIK1624422 Webwww.erytech.com Phone(347) 874-4438Fax33-4-78-75-56-29Employees196Year FoundedN/ACompany Calendar Today7/04/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.67 Current Ratio2.00 Quick Ratio2.00 Sales & Book Value Annual Sales$4.95 million Price / Sales7.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book1.29Miscellaneous Outstanding Shares31,019,000Free FloatN/AMarket Cap$34.74 million OptionableNot Optionable Beta2.02 ERYTECH Pharma Frequently Asked Questions Should I buy or sell ERYTECH Pharma stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ERYTECH Pharma in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ERYTECH Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ERYP, but not buy additional shares or sell existing shares. View analyst ratings for ERYTECH Pharma or view top-rated stocks. How has ERYTECH Pharma's stock price performed in 2022? ERYTECH Pharma's stock was trading at $2.35 at the start of the year. Since then, ERYP stock has decreased by 52.3% and is now trading at $1.12. View the best growth stocks for 2022 here. Who are ERYTECH Pharma's key executives? ERYTECH Pharma's management team includes the following people: Mr. Gil Beyen BVBA, CEO & Director (Age 60, Pay $575.51k)Mr. Eric Soyer Ph.D., Deputy GM, CFO & COO (Age 56, Pay $392.12k)Dr. Jérôme Bailly Pharm.D., Deputy GM of Operations, Chief Quality Officer & Qualified Person (Age 43, Pay $241.36k)Dr. Stewart Craig, Chief Technical Officer (Age 60)Naomi Eichenbaum, Director Investor RelationsMr. Brian Schwab, Chief Legal Officer & Gen. Counsel (Age 57)Ms. Anne-Cécile Fumey, HR Director (Age 47)Dr. Iman El-Hariry M.D., Ph.D., Chief Medical Officer (Age 62)Dr. Philip L. Lorenzi, Consultant & Member of Scientific BoardProf. Eric Raymond M.D., Ph.D., Consultant & Member of Scientific Board Who are some of ERYTECH Pharma's key competitors? Some companies that are related to ERYTECH Pharma include Finch Therapeutics Group (FNCH), Genenta Science (GNTA), Armata Pharmaceuticals (ARMP), Compugen (CGEN), Passage Bio (PASG), Big Cypress Acquisition (BCYP), Cellectis (CLLS), Athira Pharma (ATHA), Oyster Point Pharma (OYST), Adverum Biotechnologies (ADVM), Axcella Health (AXLA), TCR2 Therapeutics (TCRR), Surrozen (SRZN), BioAtla (BCAB) and Fusion Pharmaceuticals (FUSN). View all of ERYP's competitors. What other stocks do shareholders of ERYTECH Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ERYTECH Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Gilead Sciences (GILD), MEI Pharma (MEIP), Verastem (VSTM) and ACADIA Pharmaceuticals (ACAD). When did ERYTECH Pharma IPO? (ERYP) raised $125 million in an initial public offering (IPO) on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager. What is ERYTECH Pharma's stock symbol? ERYTECH Pharma trades on the NASDAQ under the ticker symbol "ERYP." How do I buy shares of ERYTECH Pharma? Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ERYTECH Pharma's stock price today? One share of ERYP stock can currently be purchased for approximately $1.12. How much money does ERYTECH Pharma make? ERYTECH Pharma (NASDAQ:ERYP) has a market capitalization of $34.74 million and generates $4.95 million in revenue each year. How many employees does ERYTECH Pharma have? ERYTECH Pharma employs 196 workers across the globe. How can I contact ERYTECH Pharma? ERYTECH Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The official website for ERYTECH Pharma is www.erytech.com. The company can be reached via phone at (347) 874-4438, via email at investors@erytech.com, or via fax at 33-4-78-75-56-29. This page (NASDAQ:ERYP) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
